6 completed, 4 terminated, 1 active not recruiting, 1 recruiting. 13 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 6, Terminated 4, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 3, Terminated 3, Withdrawn 1 |
Follow Advanced Accelerator Applications: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer [177Lu]Lu-PSMA-617, Ipilimumab - Very High Risk Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | University Hospital, Essen | 1 | 2025-08-25 | 2026-03-13 |
| Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors Cabozantinib, Lu-177 - Neuroendocrine Tumors | Phase 1 | Active not recruiting | Providence Health & Services | 6 | 2022-12-28 | 2026-04-13 |
| Lutathera and ASTX727 in Neuroendocrine Tumours ASTX727, Lutathera - Neuroendocrine Tumors | Phase 1 | Recruiting | Imperial College London | 37 | 2022-04-25 | 2026-11-12 |
| EBRT + Lu-PSMA for N1M0 Prostate Cancer 177Lu-PSMA-617, EBRT - Prostatic Neoplasm | Phase 1 | Completed | The Netherlands Cancer Institute | 14 | 2021-12-20 | 2025-12-10 |
| Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents 177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT) - Neuroendocrine Tumors, Pheochromocytoma | Phase 1 / Phase 2 | Withdrawn | Sue O'Dorisio | 2020-08-04 | 2021-06-08 | |
| 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours 177Lu-DOTA-TATE + olaparib - Clinical Trial, Phase I, Neuroendocrine Tumors | Phase 1 | Completed | Vastra Gotaland Region | 18 | 2020-04-23 | 2026-04-14 |
| [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake [177Lu]-NeoB, [68Ga]-NeoB, LCZ696 - Neoplasms | Phase 1 / Phase 2 | Completed | Advanced Accelerator Applications | 35 | 2019-07-24 | 2026-07-28 |
| 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer 177Lu-PSMA-R2 - Prostatic Neoplasm | Phase 1 | Terminated | Advanced Accelerator Applications | 27 | 2018-05-24 | 2025-05-13 |
| 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) [68Ga]-PSMA-R2 - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Completed | Advanced Accelerator Applications | 30 | 2018-05-23 | 2020-11-17 |
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate - Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Completed | Georgetown University | 9 | 2017-11-20 | 2021-03-16 |
| Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis 99mTc-Annexin V-128 SPECT - Endocarditis, Thrombosis | Phase 1 / Phase 2 | Terminated | Institut National de la Santé Et de la Recherche Médicale, France | 11 | 2016-02-05 | 2021-08-26 |
| 99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS) 99mTc-rhAnnexin V-128 - Rheumatoid Arthritis, Ankylosing Spondylitis | Phase 1 / Phase 2 | Terminated | Advanced Accelerator Applications | 16 | 2014-12-11 | 2020-10-08 |
| 99mTc-rhAnnexin V-128: a First In Man Study in Healthy Volunteers Kit for the Preparation of 99mTc-rhAnnexin V-128 - Healthy Adult Volunteers | Phase 1 | Completed | Advanced Accelerator Applications | 14 | 2013-04-01 | 2019-11-21 |
Neuroendocrine Tumors (4) · Neoplasms (3) · Prostatic Neoplasms (3) · Genital Neoplasms, Male (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Neoplasms (2) · Arthritis, Rheumatoid (1) · Endocarditis (1) · Genital Diseases, Male (1) · Mesothelioma (1) · Paraganglioma (1) · Pheochromocytoma (1) · Small Cell Lung Carcinoma (1) · Spondylitis, Ankylosing (1)
lutetium Lu 177 dotatate (4) · Ipilimumab (1) · Lutetium-177 (1) · Nivolumab (1) · Pluvicto (1) · Receptor Protein-Tyrosine Kinases (1) · Valsartan (1) · cabozantinib (1) · decitabine and cedazuridine drug combination (1) · olaparib (1) · sacubitril (1) · sacubitril and valsartan sodium hydrate drug combination (1)
United States (6) · France (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Austria (1) · Canada (1) · Germany (1) · Sweden (1) · Switzerland (1)
Chul Kim, MD (1) · Dominique Le Guludec, MD, PhD (1) · Hagen Kennecke, MD (1) · John Prior, MD, PhD (1) · M. Sue O'Dorisio, MD, PhD (1) · Rohini Sharma, Professor (1) · Terrence D. Rudy, MD, FRCPC (1) · Wouter V Vogel, MD, PhD (1)
PMID 32616557, PMID 33189510, PMID 34829796, PMID 36959540, PMID 37879695, PMID 38753757, PMID 39915126
2017 (1), 2019 (1), 2023 (1)